BioSpace News Archive

Intelligent Bio Solutions Inc. today announced the successful completion of a key development milestone in its plans to add ketamine and tramadol to its Intelligent Fingerprinting Drug Screening System.

Pressure BioSciences, Inc. announced a key transition in its collaborations with multiple leaders and innovators in global biopharmaceutical development and commercialization, including preeminent Contract Development and Manufacturing Organizations.

The global brain computer interface market size is estimated to hit around USD 9,445.1 million by 2032 up from USD 2,130 million in 2022, expanding at a healthy CAGR of 16.7% from 2023 to 2032.

Quest Diagnostics Incorporated (NYSE: DGX), the world’s leading provider of diagnostic information services, announced that Sam Samad, Executive Vice President and Chief Financial Officer, will speak on the company’s strategy, performance and the latest market developments and trends during a fireside chat at the Baird 2023 Global Healthcare Conference in New York City on Wednesday, September 13, 2023.

Rhythm Pharmaceuticals, Inc. announced that on Sept. 5, 2023, the Compensation Committee of Rhythm’s board of directors granted inducement equity grants covering an aggregate of 25,455 shares of its common stock to six new employees, consisting of inducement stock options to purchase an aggregate of 16,970 shares of common stock and inducement restricted stock units, or RSUs, covering an aggregate of 8,485 shares of its common stock.

Regeneron Pharmaceuticals, Inc. announced that Kathryn Guarini, Ph.D., and David P. Schenkein, M.D., have joined Regeneron’s Board of Directors effective September 8, 2023.

Moderna, Inc. (Nasdaq:MRNA) has been notified that TRC Capital Investment Corporation (TRC Capital) has made an unsolicited “mini-tender” offer to purchase up to 1,000,000 shares of Moderna’s common stock, at an offer price of $107.56 per share.

Antibe Therapeutics Inc. (TSX: ATE, OTCQX: ATBPF), a clinical-stage company leveraging its hydrogen sulfide platform to develop next-generation therapies to target inflammation, is pleased to announce the results of its annual meeting of shareholders (the “Meeting”) held earlier today.

EQUASHIELD is thrilled to announce its remarkable achievement of being named by the Pharmacy Purchasing & Products as the most used device in the preparation and administration of hazardous drugs for five consecutive years.

The U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency.